Step 5: Effective Drug Treatment of HIV
See also Antiretroviral Therapy, Adherence, and Initiating Treatment
Active Resources: 41
Self-Study Materials
-
2/28/2018
Antiretroviral Guidelines
-
10/27/2017
-
8/6/2015 (reviewed: 10/19/2017)
-
3/3/2015 (reviewed: 4/27/2017)
Online Training
-
10/20/2017
-
8/23/2017
Pocket Guides
-
5/1/2017
-
2/1/2014
Clinical Reference Tools
-
4/28/2017
Webinars
-
1/12/2017
-
6/8/2016
-
10/26/2015
-
7/1/2015
-
2/19/2015
-
3/28/2014
Toolkits
-
5/17/2016
-
2/2/2016
-
4/29/2015
-
7/31/2014 (reviewed: 2/12/2018)
Image Library
-
4/6/2016
Primary Care Guidelines
-
11/9/2015
-
11/13/2013
Charts, Tables & Posters
-
9/4/2015
-
7/1/2015
-
8/22/2014
Slide Sets
-
8/11/2015
-
6/11/2015
-
5/19/2015
-
12/22/2014 (reviewed: 7/17/2015)
-
1/15/2014
Videos
-
7/17/2014
-
9/2/2013
Patient Information
-
7/7/2014
-
9/29/2013 (reviewed: 2/24/2017)
Articles & Bibliographies
-
4/21/2014
-
4/21/2014
-
3/6/2014
-
2/14/2014
Coinfection Guidelines (Hep, TB, STIs)
-
3/27/2014 (reviewed: 10/31/2016)
Manuals
-
11/1/2013
Fact Sheets
-
2/1/2007
Archive Resources: 15
Clinical Reference Tools
-
9/10/2015
Slide Sets
-
4/11/2014
-
12/1/2011
-
7/8/2011
Pocket Guides
-
7/1/2013
-
4/1/2013
Charts, Tables & Posters
-
6/1/2013 (reviewed: 1/11/2017)
-
1/1/2013
-
7/1/2011
Webinars
-
2/19/2013
Curricula
-
11/1/2012
Articles & Bibliographies
-
11/1/2012
OIs & Complications Guidelines
-
1/1/2012
Fact Sheets
Self-Study Materials
-
1/1/2010
Articles: 12
-
Rifampin Drug-Drug Interactions with Newer Antiretrovirals (TAF, Bictegravir, Dolutegravir)
Treatment of tuberculosis (TB) in HIV-infected persons remains challenging, in part because of drug interactions between rifampin and some ARVs that may compromise antiretroviral therapy (ART). Three studies presented at CROI provide clinicians with additional guidance on how to manage certain...
-
Ibalizumab Approved for Persons with Multidrug Resistant HIV
Ibalizumab (TNX-355), an entry inhibitor, has been approved by the FDA for use in persons with an extensive ARV treatment history and multidrug resistant HIV who are on a failing ARV regimen. Ibalizumab (trade name: Trogarzo) is a monoclonal antibody that binds the CD4 receptor and blocks HIV...
-
Recap: 17th Ryan White HIV/AIDS Program Clinical Care Conference
Highlights from Laura W. Cheever, MD, ScM, HRSA HIV/AIDS Bureau Associate Administrator and Conference Co-Chair
The field of HIV/AIDS care and treatment continues to evolve rapidly. Groundbreaking developments in HIV research are regularly presented at international meetings and...
-
CROI 2017: Failure of Dolutegravir Monotherapy
Leading up to this year, some researchers and clinicians had optimistically viewed dolutegravir an invincible ARV, a drug so mighty that it was unlikely to fail, and even more unlikely to be victim to emergent resistance mutations. Two presentations at CROI demonstrated the...
-
Efavirenz, Dolutegravir, and Darunavir: Pharmacokinetics during Pregnancy
Three studies presented at the 2016 Conference on Retroviruses and Opportunistic Infections (CROI) explored the pharmacokinetics of antiretrovirals administered during pregnancy. These studies support the use of standard-dose efavirenz, once-daily dolutegravir, and BID ritonavir-boosted...
-
Switching from TDF/FTC to TAF/FTC
Researchers at the 2016 Conference on Retroviruses and Opportunistic Infections presented results from a randomized double-blind, double-dummy switch study of TAF/FTC. Over 660 patients with virologic suppression on TDF/FTC-containing 3-drug regimens were either switched to TAF/FTC (200/10 mg...
-
FDA Approves New TAF-Containing Analogue of Complera; Complera Approved for Pediatrics
The FDA has approved a single-pill combination of rilpivirine + emtricitabine + tenofovir alafenamide (TAF); its brand name is Odefsey.
It is intended for initial treatment of HIV-1-infected persons age 12 years and older whose pretreatment HIV RNA is ≤100,000 copies/mL, or as a substitute...
-
Pyrimethamine Availability
Pyrimethamine is no longer available in retail pharmacies in the United States, though it is available through a commercial specialty pharmacy program (the application process, approval, and delivery of the medication will take at least 2 days; for information on ordering, click...
-
Rilpivirine Updates: Approved for Adolescents; Possible Risk of Depression
The U.S. Food and Drug Administration has approved rilpivirine for use in adolescents 12 to 18 years of age; it is not recommended for younger children. As in adults, it is suggested for use in ARV-naive individuals with HIV RNA levels of ≤100,000 copies/mL. The dosage is 25 mg...
-
Adult and Adolescent Guidelines: Major Changes
The U.S. Department of Health and Human Services has released new treatment guidelines for adults and adolescents, and these contain some important changes. Key among these is a major shakeup in the "Recommended Regimen Options" for initial therapy.
Efavirenz/TDF/FTC (Atripla) has... -
Two New Boosted-PI Coformulations
Two boosted protease inhibitor (PI) coformulations have just been approved by the FDA. These are:
Darunavir 800 mg + cobicistat 150 mg (Prezcobix), andAtazanavir 300 mg + cobicistat 150 mg (Evotaz)In these fixed-dose combinations, cobicistat is used as the pharmacokinetic booster of the PI...
-
Efavirenz Updates: Bone Mineral Density & Suicidality
Efavirenz and Bone Mineral DensityPersons with HIV infection have a number of risk factors for decreased bone mineral density (BMD), related not just to effects of HIV or resulting illness but also to ART. For example, BMD decreases by as much as 5-6% after initiation of ART, and certain ARVs (...
| Day | Title |
|---|---|
|
12/2 |
| Day | Title |
|---|---|
|
3/16 |
|
|
3/4 |
CROI 2018: Boston
Event type: Conferences & Events
|
|
10/23 |